Furthermore, Vanderstichele et al. showed that changes in nucleosome positioning footprint were able to detect anti-EGFR and anti-ERBB2 therapy responsiveness in non-small-cell lung cancer, as it closely reflected expression levels of EGFR or ERBB2 mutant alleles [132]. Here, EGFR is linked to non-small cell lung carcinoma.